Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis

PHASE3CompletedINTERVENTIONAL
Enrollment

409

Participants

Timeline

Start Date

Not specified

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Erosive Esophagitis
Interventions
DRUG

TAK-438

TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.

DRUG

Placebo

"Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."

DRUG

Lansoprazole

"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."

DRUG

Placebo

TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.

Trial Locations (32)

Unknown

Nagoya

Abiko-shi

Fukuoka

Itoshima-shi

Kurume-shi

Onga-gun

Gifu

Annaka-shi

Aki-gun

Hiroshima

Sapporo

Amagasaki-shi

Kobe

Takarazuka-shi

Sakade-shi

Yokohama

Kochi

Susaki-shi

Kumamoto

Kyoto

Nagasaki

Ōita

Okayama

Fuziidera-shi

Shizuoka

Otawara-shi

Chiyoda-ku

Chuo-ku

Nakano-ku

Ōta-ku

Setagaya-ku

Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY